PRESS RELEASE
Paris, May 20, 2025
THE STERIMED GROUP BECOMES INDEPENDENT, RECOMPOSES AND STRENGTHENS ITS SHAREHOLDER BASE
STERIMED, a French company and world leader in medical packaging, announces the finalization of a capital restructuring agreement led by its management, and the implementation of a new strategic plan.
Groupe Sterimed announced today that it has reached an agreement to strengthen and recompose its capital around its management team, IK Partners ("IK"), Sagard and a group of investors in a new structure called "Les Amis de Sterimed". This operation marks a decisive step towards an ambitious new strategic plan supported by all the partners, which aims to achieve sales of €600m by 2030.
Following this operation, the management, supported by Les Amis and represented by Thibaut Hyvernat, holds around 42% of the capital and, together with IK and Sagard, now controls the governance of the group.
Thanks to IK's arrival at the table, the renewed support of Sagard, which has substantially increased its investment after having already supported the group for 5 years, and the support of an enlarged group of Friends of Sterimed to the management team, the group's financial resources have been strengthened, and its continued development assured.
The families and entrepreneurs historically associated with the group's development in Mexico, Ireland and the United Kingdom have also all wished to remain a significant shareholder, by joining the Friends of Sterimed.
We are also delighted to welcome new partner investors to Les Amis: Société Générale Capital Partenaires, GENEO Capital Entrepreneur, Capza and Investir pour l'Enfance (represented by Raise).
We would like to thank them all for the confidence they have shown in us, or renewed.
With the support of IK, Sagard and Les Amis, the Sterimed group, more than ever an Association of Entrepreneurs, will be able to pursue its development strategy, both in its traditional markets of sterile medical device packaging and in new markets such as contract packing and other associated services, infection prevention and pharmaceutical packaging.
* * * * * * * * * * * * * * * * * *
Thibaut Hyvernat, Chairman and CEO, said:
"I'm particularly pleased and proud of how far the Sterimed group has come in 8 years, and of the original entrepreneurial and human model we've been able to create. Thanks to the confidence and support of our investors, we have been able to lead this adventure from day one, making it our own collectively, with all our teams, and gradually bringing together incredible talents and energies in the service of a shared vision.
The move towards independence that we are announcing today means a great deal to us, and we are bound by the trust placed in us.
Thanks to the support of IK, Sagard and Les Amis, whom I would like to thank warmly on behalf of the entire management team and all the Group's employees, I am convinced that we can go even further and even faster, in the interests of greater patient safety.
We will strive to demonstrate this every day, while remaining true to the strong values that drive us.
About Groupe Sterimed
Over the last 5 years, Sterimed has achieved sustained growth, both organically and through external growth strategies, increasing its sales from €135m to over €300m. And all this thanks to over 1,500 highly committed employees, more than half of whom are shareholders in the group.
Sterimed is now one of the world's leading medical packaging companies, and is aiming for sales of €600m by 2030, in line with its vision: "As pioneers of a responsible medical packaging industry, we are all working together for greater patient safety".
Its ambition remains unchanged: to serve all its customers (medical device manufacturers, hospitals, the pharmaceutical industry, specialized packaging players) with the highest quality and ever-greater patient safety.
About IK Partners
IK Partners ("IK") is a European private equity firm with a presence in the Benelux, the DACH region, France, the Nordic countries and the UK. Since 1989, IK has raised over €19 billion and invested in more than 200 European companies. IK accompanies companies with strong growth potential, alongside management teams and investors, to create robust, well-positioned businesses with excellent long-term prospects.
For further information, visit www.ikpartners.com
About Sagard
Sagard is a French investment fund that provides equity capital to support the development of mid-sized companies led by ambitious teams. Founded in 2003 with the support of the Desmarais family, Sagard's investors include influential industrial families and leading institutional investors. Since its creation, Sagard and its team of 14 professionals based in Paris and Milan have invested in 50 industrial and service companies in France.
For more information, visit www.sagard.eu
Contacts :
For further information or media requests, or any questions concerning this press release, please contact :
Sterimed
Dorothée Vuibert - Group Communications Director - dorothee.vuibert@sterimed.fr
IK Partners
Vidya Verlkumar - Communications and Marketing Director - vidya.verlkumar@ikpartners.com
GENEO Capital Entrepeneur
Bien Commun Advisory :
Hugues de Tournemine - 06 67 07 22 33 - h.detournemire@bcadvisory.fr
Frédéric Paillet - 01 43 35 49 84 - f.paillet@bcadvisory.fr
